Scarica l'app Stockscreener
177.67
3.15%
5.42
Dopo l'orario di chiusura:
177.67
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BDX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$172.25
Aprire:
$172.21
Volume 24 ore:
3.22M
Relative Volume:
1.12
Capitalizzazione di mercato:
$49.98B
Reddito:
$20.87B
Utile/perdita netta:
$1.50B
Rapporto P/E:
33.91
EPS:
5.24
Flusso di cassa netto:
$2.59B
1 W Prestazione:
+3.56%
1M Prestazione:
+2.94%
6M Prestazione:
-21.69%
1 anno Prestazione:
-22.51%
Intervallo 1D:
$171.32
$179.12
Intervallo di 1 settimana:
$168.89
$179.12
Portata 52W:
$163.33
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Nome
Becton Dickinson Co
Settore
Industria
Telefono
(201) 847-6800
Indirizzo
ONE BECTON DR, FRANKLIN LAKES
Confronta BDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
177.67 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
537.99 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
89.02 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
256.26 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
222.42 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-02 | Downgrade | Goldman | Buy → Neutral |
| 2025-05-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-05-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-12-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2022-07-11 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Ripresa | Raymond James | Mkt Perform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2021-12-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2020-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Ripresa | Goldman | Buy |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-07 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-02-07 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-01-08 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Iniziato | Deutsche Bank | Buy |
| 2018-10-16 | Iniziato | Barclays | Equal Weight |
| 2018-06-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-01-19 | Ripresa | BofA/Merrill | Buy |
| 2018-01-05 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-01-05 | Iniziato | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2017-12-29 | Reiterato | Deutsche Bank | Buy |
Mostra tutto
Becton Dickinson Co Borsa (BDX) Ultime notizie
YieldBoost Becton, Dickinson From 2.5% To 15.5% Using Options - Nasdaq
BD upgrades laboratory in Suzhou - China Daily
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift - Investing.com
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift By Investing.com - Investing.com India
Becton Dickinson Stock Price, Quotes and Forecasts | NYSE:BDX - Benzinga
Medical technology firm BD looks to bring products to more PHL hospitals - BusinessWorld Online
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead By Investing.com - Investing.com South Africa
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead - Investing.com Australia
Becton, Dickinson And Co To Present At Goldman Sachs Conference; Webcast At 2:00 PM ET - Nasdaq
Stifel maintains Becton Dickinson stock with a $224 target - Investing.com
Here's How You Can Earn $100 In Passive Income By Investing In Becton Dickinson Stock - Yahoo Finance
Barclays Lowers Becton, Dickinson & Co. (BDX) Price Target, Maintains Overweight Rating - MSN
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
BD’s Future Plans: Shed Life Sciences to Fund Medical Technology - Lab Manager
How Is Becton, Dickinson and Company’s Performance Compared to Other Medical Instruments & Supplies Stocks? - Barchart.com
Becton Dickinson (BDX) Maintains Overweight Rating Despite Price Target Cut | BDX Stock News - GuruFocus
Barclays lowers Becton Dickinson stock price target to $241 By Investing.com - Investing.com South Africa
Barclays Adjusts Price Target on Becton, Dickinson and Company to $241 From $261 - marketscreener.com
Barclays lowers Becton Dickinson stock price target to $241 - Investing.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barcl - GuruFocus
Becton Dickinson and : BD Vascular Access Management Recognized with Seal of Approval from Infusion Nurses Society - marketscreener.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barclays | BDX Stock News - GuruFocus
Becton Dickinson EVP David Shan Sells Shares and Other Important Updates - TradingView
Insider Sell: David Shan Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - Becton Dickinson
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News
Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut b - GuruFocus
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut by Citigroup | BDX Stock News - GuruFocus
6 Analysts Have This To Say About Becton Dickinson - Benzinga
Becton Dickinson (BDX) Downgraded by Citi to Neutral | BDX Stock News - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challen - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challenges | BDX Stock News - GuruFocus
Citigroup Downgrades Becton Dickinson and Co. to Neutral From Buy, Adjusts PT to $185 From $217 - marketscreener.com
BD aims to secure slice of medical technology market - BusinessMirror
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' - BD Newsroom
Employees return to work at North Canaan plant where suspicious package was delivered, officials say - CT Insider
FBI probes North Canaan suspicious package that contaminated hundreds: What we know and don't know - CT Insider
Becton, Dickinson and Company Stock: Analyst Estimates & Ratings - inkl
Becton, Dickinson and Company (BDX): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Health dept. clears BD to reopen facility after hazmat scare - The Lakeville Journal
Argus Adjusts Price Target on Becton Dickinson and Co. to $220 From $270, Maintains Buy Rating - marketscreener.com
Becton Dickinson Co Azioni (BDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):